The following article appeared on February 21, 2025 on Law360 UK. The Rise of GLP-1 Agonists The rapid ascent of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) — such as Novo Nordisk’s Ozempic and Wegovy, and Eli Lilly & Co.’s Mounjaro and Zepbound — has revolutionized diabetes management and weight loss. However, this surge has triggered […]